Emgality ® (galkanezumab)

För fullständig produktresumé för Emgality® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Emgality® ▼ (galcanezumab): Skillnader i molekylära mål

Det är okänt om skillnader i det molekylära målet för CGRP monoklonala antikroppar (dvs peptid eller receptor) är kliniskt relevanta.

The Role of CGRP in Migraine

The CGRP neuropeptide has been

  • extensively studied, and

  • implicated in the pathophysiology of migraine.1

It has been shown that

  • CGRP activates both CGRP and AMY1 receptors, and

  • CGRP and AMYreceptors are both present in the trigeminal pathway.2

The role of the AMY1 receptor in migraine is not yet clear.2

Molecular Targets of CGRP mAbs

CGRP mAbs have been engineered to bind to either CGRP or the receptor.3,4

Galcanezumab is a humanized IgG4 mAb that

  • binds CGRP, thus

  • preventing its biological activity.5

CGRP receptor mAbs, such as erenumab,

  • bind to the CGRP receptor, and

  • antagonize the CGRP receptor function.6

It is currently unknown how this difference in mechanism of action between CGRP receptor and peptide mAbs translates clinically.

References

1. Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: A disorder of sensory processing. Physiol Rev. 2017;97(2):553-622. http://dx.doi.org/10.1152/physrev.00034.2015

2. Walker CS, Eftekhari S, Bower RL, et al. A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol. 2015;2(6):595-608. http://dx.doi.org/doi:10.1002/acn3.197

3. Raffaelli B, Reuter U. The biology of monoclonal antibodies: focus on calcitonin gene-related peptide for prophylactic migraine therapy. Neurotherapeutics. 2018;15(2):324-335. http://dx.doi.org/10.1007/s13311-018-0622-7

4. Silberstein S, Lenz R, Xu C. Therapeutic monoclonal antibodies: what headache specialists need to know. Headache. 2015;55(8):1171-1182. http://dx.doi.org/10.1111/head.12642

5. Emgality [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

6. Aimovig [package insert]. Thousand Oaks, CA: Novartis; 2018.

Glossary

AMY1 = amylin

CGRP = calcitonin gene-related peptide

IgG4 = immunoglobulin G (subclass) 4

mAb = monoclonal antibody

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Datum fӧr senaste ӧversyn 2018 M09 05


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss